The third FDA-cleared Alzheimer's blood biomarker test is PrecivityAD2, cleared August 20, 2026 for adults age 40 and older with signs of cognitive impairment. What changed is the age floor, and what comes next is earlier evaluation for younger-onset families plus wider clinical use. According to C2N Diagnostics, the test helps rule amyloid pathology in or out alongside clinical workup C2N announcement.
A blood biomarker test measures Alzheimer's-related proteins in blood. Amyloid pathology means harmful amyloid buildup in the brain. For families facing symptoms in the 40s, this offers a less invasive first step than a PET scan or spinal tap.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from C2N — Use this primary source to verify the official guidance.
- Read the official guidance from Alz — Use this primary source to verify the official guidance.
Table of Contents
- What makes this test different?
- Who is it for?
- What are the limits?
- What can families do now?
- What comes next?
What makes this test different?
The two earlier clearances were Fujirebio's Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio in May 2025 and Roche's Elecsys pTau181 plasma test in October 2025. According to the Alzheimer's Association, both were limited to adults 55 and older Alzheimer's Association report. PrecivityAD2 starts at age 40. That is fifteen years younger.
It is the first FDA-cleared blood option for younger-onset evaluation. The method also differs. It uses high-resolution mass spectrometry in one blood draw. It measures p-Tau217, a phosphorylated tau protein linked to Alzheimer's, plus Aβ42/40 ratios, a comparison of two amyloid fragments. An algorithm turns those results into a score.
Who is it for?
The test is for adults 40 and older who already have signs of cognitive impairment. Signs can include ongoing memory loss, confusion, word-finding trouble, or loss of daily skills.
A clinician must judge whether testing fits. Those affected include about 200,000 Americans under 65 with younger-onset disease plus millions of older adults with symptoms. For them, the blood draw can reduce the need for PET imaging or lumbar puncture at the start.
- Age 40 or older
- Ongoing cognitive symptoms, not normal forgetfulness
- Clinical exam and history to guide testing
- Doctor order and counseling about results
What are the limits?
PrecivityAD2 is not a screen for healthy people in their 40s. It is meant for people with symptoms. Amyloid is less common at younger ages, so pre-test risk matters. According to Medical News Today, results depend heavily on symptoms and broader clinical assessment Medical News Today report.
A low score helps rule amyloid out. A high score helps rule it in. Neither replaces diagnosis alone. Other brain conditions can cause similar symptoms in midlife. Families should expect follow-up exams, cognitive testing, and often referral to a memory specialist.
What can families do now?
Ask the primary care doctor or neurologist whether the case meets the use criteria. Bring a symptom timeline, medication list, sleep and mood history, and a family member who sees daily function. Ask how the result would change next steps.
Initial access runs through C2N's clinical laboratory, with wider clinician rollout later in 2026. That path can support earlier care planning, specialist referral, clinical trial screening, and treatment-eligibility workup. Confirm insurance coverage, out-of-pocket cost, and sample handling before the draw.
What comes next?
A fourth FDA-cleared Alzheimer's blood test followed within days in August 2026. It was Roche's single-biomarker Elecsys pTau217 test for rule-in and rule-out use. More blood options may speed triage, but symptoms plus clinical judgment still decide who should be tested.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- Home-Based Dementia Care Research Priorities in 2026: What Changed and What Comes Next for Adult Children
